News &amp; Updates

Hepatic steatosis may raise the risk of major adverse cardiovascular events through increased non-calcified plaque burden, according to a study.

Hepatic steatosis increases non-calcified plaque burden

Dysphagia a red flag for poor outcomes after cardiovascular procedures

08 Jul 2026 by

Among individuals undergoing common cardiovascular procedures, those with a preoperative diagnosis of dysphagia face an increased risk of postoperative mortality and complications, according to a retrospective study.

Dysphagia a red flag for poor outcomes after cardiovascular procedures

Camrelizumab plus apatinib shows promising safety, efficacy in ESCC

Treatment with camrelizumab combined with apatinib demonstrates improvements in overall survival (OS), progression-free survival (PFS), and response rates in patients with esophageal squamous cell carcinoma (ESCC), a study has shown.

Camrelizumab plus apatinib shows promising safety, efficacy in ESCC

No clear link between prenatal acid suppressant use and IBD in offspring

In vitro exposure to acid-suppressive medications does not appear to be associated with an increased risk of inflammatory bowel disease (IBD) development in offspring, as shown in a nationwide cohort study.

No clear link between prenatal acid suppressant use and IBD in offspring

MELD best predictor of outcomes in alcohol-related liver disease: study

A recent study describes the natural history of alcohol-associated liver disease (ALD) and the risks of outcomes based on the model for end-stage liver disease (MELD) score across the ALD spectrum.

MELD best predictor of outcomes in alcohol-related liver disease: study

Beta-blocker therapy confers survival benefit in viral hepatitis-related cirrhosis

Among patients with viral hepatitis-related cirrhosis who sustained non-bleeding decompensating events, the use of non-selective beta blockers is associated with lower mortality, as shown in a study.

Beta-blocker therapy confers survival benefit in viral hepatitis-related cirrhosis

Switching to entecavir reduces relapse, flare in HBeAg-negative patients

In hepatitis B e antigen-negative (HBeAg) patients, the last antiviral agent used prior to end of therapy (EOT) appears predictive of the timing of clinical relapse, according to a study. An entecavir-switching strategy may prevent relapse and reduce hepatitis flare and its severity within 24 weeks after EOT.

Switching to entecavir reduces relapse, flare in HBeAg-negative patients

Anticoagulants up risk of bleeding after esophageal dilation procedure

Patients taking anticoagulant medications at the time of esophageal dilation are at increased risk of experiencing gastrointestinal bleeding after the procedure, suggests a study.

Anticoagulants up risk of bleeding after esophageal dilation procedure